According to Halozyme Therapeutics's latest financial reports the company's current earnings are โน1.01 Billion. , an increase over its 2023 earnings that were of โน29.79 Billion. The earnings displayed on this page is the company's Pretax Income.
Year | Earnings | Change |
---|---|---|
2024 | โน47.66 B | 59.94% |
2023 | โน29.79 B | 39.94% |
2022 | โน21.29 B | 0.16% |
2021 | โน21.26 B | 92.2% |
2020 | โน11.06 B | -278.96% |
2019 | -โน6.19 Billion | -9.45% |
2018 | -โน6.83 Billion | -229.51% |
2017 | โน5.27 B | -160.48% |
2016 | -โน8.72 Billion | 216.03% |
2015 | -โน2.76 Billion | -52.86% |
2014 | -โน5.85 Billion | -18.09% |
2013 | -โน7.15 Billion | 55.88% |
2012 | -โน4.59 Billion | 169.94% |
2011 | -โน1.7 Billion | -63.44% |
2010 | -โน4.65 Billion | -7.19% |
2009 | -โน5.01 Billion | 15.91% |
2008 | -โน4.32 Billion | 83.89% |
2007 | -โน2.35 Billion | 78.1% |
2006 | -โน1.32 Billion | 16% |
2005 | -โน1.14 Billion | 45.24% |
2004 | -โน0.79 Billion | 682.42% |
2003 | -โน99.94 Million | 1659.12% |
2002 | -โน5.69 Million |